ANI PHARMACEUTICALS, INC Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ANI PHARMACEUTICALS, INC (ANIP) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$152.67 million for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2016-11-03
- ANI PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-09-30 was -$1.09M.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-06-30 was -$66.03M.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-03-31 was -$85.55M.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2015-12-31 was -$1.10M.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$32.68M.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$35.75M, a 276.41% decline from fiscal 2013.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was $20.27M.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) investing activities, continuing operations for fiscal 2012 was -$292.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-09-30 | -$1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$67.12M derived: sum of 2 quarters · filed 2016-11-03 | -$152.67M 10-Q · filed 2016-11-03 | -$153.78M derived: sum of 4 quarters · filed 2016-11-03 | ||||
| 2016-06-30 | -$66.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$151.58M 10-Q · filed 2016-08-04 | -$152.69M derived: sum of 3 quarters · filed 2016-08-04 | -$179.46M derived: sum of 4 quarters · filed 2016-11-03 | ||||
| 2016-03-31 | -$85.55M 10-Q · filed 2016-05-05 | -$86.66M derived: sum of 2 quarters · filed 2016-05-05 | -$113.42M derived: sum of 3 quarters · filed 2016-11-03 | -$113.62M derived: sum of 4 quarters · filed 2016-11-03 | ||||
| 2015-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | -$27.87M derived: sum of 2 quarters · filed 2016-11-03 | -$28.07M derived: sum of 3 quarters · filed 2016-11-03 | -$32.68M 10-K · filed 2016-02-23 | ||||
| 2015-09-30 | -$26.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$26.97M derived: sum of 2 quarters · filed 2016-11-03 | -$31.58M 10-Q · filed 2016-11-03 | -$31.92M derived: sum of 4 quarters · filed 2016-11-03 | ||||
| 2015-06-30 | -$198.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$4.81M 10-Q · filed 2016-08-04 | -$5.15M derived: sum of 3 quarters · filed 2016-08-04 | -$27.68M derived: sum of 4 quarters · filed 2016-08-04 | ||||
| 2015-03-31 | -$4.61M 10-Q · filed 2016-05-05 | -$4.95M derived: sum of 2 quarters · filed 2016-05-05 | -$27.48M derived: sum of 3 quarters · filed 2016-05-05 | -$27.73M derived: sum of 4 quarters · filed 2016-05-05 | ||||
| 2014-12-31 | -$338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | -$22.87M derived: sum of 2 quarters · filed 2016-02-23 | -$23.12M derived: sum of 3 quarters · filed 2016-02-23 | -$35.75M 10-K · filed 2016-02-23 | ||||
| 2014-09-30 | -$22.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$22.78M derived: sum of 2 quarters · filed 2014-11-10 | -$35.42M 10-Q · filed 2014-11-10 | -$33.19M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2014-06-30 | -$253.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$12.89M 10-Q · filed 2014-08-07 | -$10.66M derived: sum of 3 quarters · filed 2016-02-23 | -$10.69M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2014-03-31 | -$12.63M 10-Q · filed 2014-05-12 | -$10.40M derived: sum of 2 quarters · filed 2016-02-23 | -$10.44M derived: sum of 3 quarters · filed 2016-02-23 | $7.74M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2013-12-31 | $2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $2.20M derived: sum of 2 quarters · filed 2016-02-23 | $20.38M derived: sum of 3 quarters · filed 2016-02-23 | $20.27M 10-K · filed 2016-02-23 | ||||
| 2013-09-30 | -$34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $18.14M derived: sum of 2 quarters · filed 2014-11-10 | $18.04M 10-Q · filed 2014-11-10 | $18.04M 10-Q · filed 2013-11-07 | $17.82M derived: sum of 4 quarters · filed 2014-11-10 | |||
| 2013-06-30 | $18.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $18.07M 10-Q · filed 2014-08-07 | $18.07M 10-Q · filed 2013-08-09 | $17.85M derived: sum of 3 quarters · filed 2014-08-07 | $17.85M derived: sum of 4 quarters · filed 2014-08-07 | |||
| 2013-03-31 | -$108.00K 10-Q · filed 2014-05-12 | -$1.26M 10-Q · filed 2013-05-10 | -$323.11K derived: sum of 2 quarters · filed 2014-05-12 | -$330.90K derived: sum of 3 quarters · filed 2014-05-12 | -$337.81K derived: sum of 4 quarters · filed 2014-05-12 | |||
| 2012-12-31 | -$215.11K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | -$222.90K derived: sum of 2 quarters · filed 2014-02-28 | -$229.81K derived: sum of 3 quarters · filed 2014-02-28 | -$292.00K 10-K · filed 2014-02-28 | -$619.15K 10-K · filed 2013-02-28 | |||
| 2012-09-30 | -$7.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$14.70K derived: sum of 2 quarters · filed 2013-11-07 | -$76.89K 10-Q · filed 2013-11-07 | -$536.70K 10-Q · filed 2012-11-08 | -$151.21K derived: sum of 4 quarters · filed 2013-11-07 | |||
| 2012-06-30 | -$6.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$69.10K 10-Q · filed 2013-08-09 | -$71.26K 10-Q · filed 2012-08-01 | -$143.42K derived: sum of 3 quarters · filed 2013-08-09 | -$246.10K derived: sum of 4 quarters · filed 2013-08-09 | |||
| 2012-03-31 | -$62.19K 10-Q · filed 2013-05-10 | -$136.51K derived: sum of 2 quarters · filed 2013-05-10 | -$239.19K derived: sum of 3 quarters · filed 2013-05-10 | -$560.88K derived: sum of 4 quarters · filed 2013-05-10 | ||||
| 2011-12-31 | -$74.32K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | -$177.01K derived: sum of 2 quarters · filed 2013-02-28 | -$498.70K derived: sum of 3 quarters · filed 2013-02-28 | -$719.92K 10-K · filed 2013-02-28 | ||||
| 2011-09-30 | -$102.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$424.37K derived: sum of 2 quarters · filed 2012-11-08 | -$645.60K 10-Q · filed 2012-11-08 | |||||
| 2011-06-30 | -$321.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | -$542.92K 10-Q · filed 2012-08-01 | ||||||
| 2011-03-31 | -$221.23K 10-Q · filed 2012-05-08 | |||||||
| 2010-12-31 | -$60.37K 10-K · filed 2013-02-28 | |||||||
| 2009-12-31 | $2.86M 8-K · filed 2013-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |